




Fig. 1A**Fig. 1B**

Fig. 2A

10/520931

PCT/EP2003/007551

WO 2004/007701

3/20



Fig. 2B

19/5/2003

WO 2004/007701

PCT/EP2003/007551

4/20



Fig. 2C





Fig. 2D

Fig. 3


7/20

Fig. 4A

8/20

Fig. 4B

9/20

Fig. 4C

10/20

LEW -> LEW, POD 14
kidney control

Fig. 4D-1




Fig. 4D-2



Fig. 4D-3




Fig. 4D-4



DA -> LEW, untreated, POD 14 TAIC treated, POD 14

Fig. 4E-1**Fig. 4E-2****Fig. 4E-3**

syngeneic, POD 12 TAIC, POD 12 untreated, POD 12
LEW > LEW DA > LEW CA > LEW



12/20



FIG. 4F

13/20


Fig. 5A


Fig. 5B


Fig. 6A

Fig. 6B-1

untreated, POD 41




Fig. 6B-2

TAIC treated, POD 55





Fig. 7

Fig. 8

suppressor function




Fig. 9




Fig.10A

day 5 after surgery prior to
cell administration




Fig.10B

day 3 after cell
administration




Fig.10C